Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template [3]

Journal of Medicinal Chemistry

Volumn 42, Issue 4, 1999, Pages 541-544

  Groneberg, Robert D ^a   Burns, Christopher J ^a   Morrissette, Matthew M ^b   Ullrich, John W ^c   Morris, Robert L ^a   Darnbrough, Shelley ^a   Djuric, Stevan W ^d   Condon, Stephen M ^a   McGeehan, Gerard M ^e   Labaudiniere, Richard ^a   Neuenschwander, Kent ^a   Scotese, Anthony C ^a   Kline, Jane A ^a  

^a SANOFI   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d ABBOTT LABORATORIES   (United States)

^e Medicinal Chemistry Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; PHOSPHODIESTERASE IV;

ANTIINFLAMMATORY ACTIVITY; DIASTEREOISOMER; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; LETTER; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; COLLAGENASES; FIBROBLASTS; GELATINASES; GUINEA PIGS; HYDROXAMIC ACIDS; MACROPHAGES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; PHOSPHODIESTERASE INHIBITORS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 0033602133     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980567e     Document Type: Letter

References (33)

1. (a) de Brito, F. B.; Souness, J. E.; Warne, P. J. Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerging Drugs 1997, 2, 249-268.
2. (b) Stafford, J. A.; Feldman, P. L. Chronic pulmonary inflammation and other therapeutic applications of PDE IV inhibitors. Annu. Rep. Med. Chem. 1996, 31, 71-80.
3. (a) Beckett, R. P.; Whittaker, M. Matrix metalloproteinase inhibitors 1998. Exp. Opin. Ther. Patents 1998, 8, 259-282.
4. (b) Levy, D. E.; Ezrin, A. M. Matrix metalloproteinase inhibitor drugs. Emerging Drugs 1997, 2, 205-230.
5. Torphy, T. J. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 1998, 157, 351-370.
6. (a) Molnar-Kimber, K. L.; Yonno, L.; Heaslip, R. J.; Weichman, B. M. Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Mediat. Inflamm. 1992, 1, 411-417.
7. (b) For a review detailing the in vitro pharmacology of PDE4, see ref 3.
8. Sekut, L.; Yarnall, D.; Stimpson, S. A.; Noel, L. S.; Bateman-Fite, R.; Clark, R. L.; Brackeen, M. F.; Menius J. A., Jr.; Connolly, K. M. Antiinflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. 1995, 110, 126-132.
9. (a) Genain, C. P.; Roberts, T.; Davis, R. L.; Nguyen, M.-H.; Uccelli, A.; Faulds, D.; Li, Y.; Hedgpeth, J.; Hauser, S. L. Prevention of autoimmune demyelination in nonhuman primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3601-3605.
10. (b) Sommer, N.; Löschmann, P.-A.; Northoff, G. H.; Weller, M.; Steinbrecher, A.; Steinbach, J. P.; Lichtenfels, R.; Meyermann, R.; Riethmüller, A.; Fontana, A.; Dichgans, J.; Martin, R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature (Medicine) 1995, 1, 244-248.
11. Hanifin, J. M.; Chan, S. C.; Cheng, J. B.; Tofte, S. J.; Henderson, W. R., Jr.; Kirby, D. S.; Weiner, E. S. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiinflammatory effects in atopic dermatitis. J. Invest. Dermatol. 1996, 107, 51-56.
12. Stawiski, M. A.; Rusin, L. J.; Burns, T. L.; Weinstein, G. D.; Voorhees, J. J. Ro 20-1724: An agent that significantly improves psoriatic lesions in double-blind clinical trials. J. Invest. Dermatol. 1979, 73, 261-263.
13. Woessner, J. F., Jr. The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 1994, 732, 11-21.
14. (a) Conway, J. G.; Wakefield, J. A.; Brown, R. H.; Marron, B. E.; Sekut, L.; Stimpson, S. A.; McElroy, A.; Menius, J. A.; Jeffreys, J. J.; Clark, R. L.; McGeehan, G. M.; Connolly, K. M. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J. Exp. Med. 1995, 182, 449-457. Sec also:
15. (b) Hirayama, R.; Yamamoto, M.; Tsukida, T.; Matsuo, K.; Obata, Y.; Sakamoto, F.; Ikeda, S. Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. Bioorg. Med. Chem. 1997, 5, 765-778.
16. Baxter, A. D.; Bird, J.; Bhogal, R.; Massil, T.; Minton, K. J.; Montana, J.; Owen, D. A. A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorg. Med. Chem. Lett. 1997, 7, 879-902.
17. Hewson, A. K.; Smith, T.; Leonard, J. P.; Cuzner, M. L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 1995, 44, 345-349.
18. Bird, J.; Montana, J. New therapeutic approaches to atopic dermatitis. Exp. Opin. Invest. Drugs 1996, 5, 1173-1180.
19. Galardy, R. E.; Cassabonne, M. E.; Giese, C.; Gilbert, J. H.; Lapierre, F.; Lopez, H.; Schaefer, M. E.; Stack, R.; Sullivan, M.; Summers, B.; Tressler, R.; Tyrrell, D.; Wee, J.; Allen, S. D.; Castellot, J. J.; Barletta, J. P.; Schultz, G. S.; Fernandez, L. A.; Fisher, S.; Cui, T.-Y.; Foellmer, H. G.; Grohelny, D.; Holleran, W. M. Low molecular weight inhibitors in corneal ulceration. Ann. N. Y. Acad. Sci. 1994, 732, 315-323.
20. MMP-1, fibroblast collagenase; MMP-2, gelatinase A; MMP-3, stromelysin-1.
21. 3N) of the alcohol. The required ketone was prepared by MeLi addition (-78°C, THF) to the N-methoxy-N-methylamide.
22. Miyata, O.; Shinada, T.; Ninomiya, I.; Naito, T.; Date, T.; Okamura, K.; Inagaki, S. Stereospecific nucleophilic addition reactions to olefins. Addition of thiols to α,β-unsaturated carboxylic acid derivatives. J. Org. Chem. 1991, 56, 6556-6564.
23. Generated as a 1:1 mixture of diastereomers in 36% yield from 5-phenylpentanal and the dilithium anion of propionic acid.
24. Capozzi, G.; Roelens, S.; Talami, S. A protocol for the efficient synthesis of enantiopure β-substituted β-lactones. J. Org. Chem. 1993, 58, 7932-7936.
25. 3,4 = 3.7 Hz). For a reference to β-lactone coupling constants, see: Mulzer, J.; Kerkmann, T. α-Deprotonation of β-lactones-an example of a "forbidden" β-elimination. J. Am. Chem. Soc. 1980, 102 3620-3622.
26. PDE4 inhibitory activity was measured as the mean of three determinations against guinea pig macrophage homogenate PDE4 according to the methods of Thompson, W. J.; Terasaki, W. L.; Epstein, P. M.; Strada, S. J. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cyclic Nucl. Res. 1979, 10, 69-92.
27. Inhibitory activity on recombinant human MMP-1, MMP-2, and MMP-3 (biogenesis) was measured according to the methods of Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
28. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
29. Kleinman, E. F.; Campbell, E.; Giordano, L. A.; Cohan, V. L.; Jenkinson, T. H.; Cheng, J. B.; Shirley, J. T.; Pettipher, E. R.; Salter, E. D.; Hibbs, T. A.; DiCapua, F. M.; Bordner, J. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNFa inhibitory activity of two series of rolipram analogues: Implications for a new active site model of PDE4. J. Med. Chem. 1998, 41, 266-270.
30. For a discussion of the use of this pharmacophore "switch" in the design and production of target family-directed small-molecule libraries (PDE4 and MMP), see: Burns, C. J.; Groneberg, R. D.; Salvino, J. M.; McGeehan, G.; Condon, S. M.; Morris, R.; Morrissette, M.; Mathew, R.; Darnbrough, S.; Neuenschwander, K.; Scotese, A.; Djuric, S. W.; Ullrich, J.; Labaudiniere, R. Nanomolar Inhibitors for Two Distinct Biological Target Families from a Single Synthetic Sequence: A Next Step in Combinatorial Library Design? Angew. Chem., Int. Ed. Engl. 1998, 37, 2848-2850.
31. The bioactive conformation of the stromelysin inhibitor 13 has been determined using NMR spectroscopy: Gonnella, N. C.; Li, Y.-C.; Zhang, X.; Paris, C. G. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg. Med. Chem. 1997, 5, 2193-2201. An X-ray crystal structure of a related sulfonamide hydroxamate bound to fibroblast collagenase (MMP-1) shows a similar binding mode: Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
32. The bioactive conformation of the stromelysin inhibitor 13 has been determined using NMR spectroscopy: Gonnella, N. C.; Li, Y.-C.; Zhang, X.; Paris, C. G. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg. Med. Chem. 1997, 5, 2193-2201. An X-ray crystal structure of a related sulfonamide hydroxamate bound to fibroblast collagenase (MMP-1) shows a similar binding mode: Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
33. 50 = 3 μM) against PDE4 than the parent compound.